Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003 Life Science Investing
Firefly Neuroscience Reports 291% Increase in TMS Center Customer Brain Scan Volumes Life Science Investing
Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference Life Science Investing
BriaCell Receives FDA Clearance to Initiate Bria-PROS+ Clinical Study in Prostate Cancer Pharmaceutical Investing
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update Life Science Investing
Summit Therapeutics Further Expands Ivonescimab Global Development Program with Phase II/III HARMONi-GU1 Study in 1L Bladder Cancer Life Science Investing
Atea Pharmaceuticals to Host Second Quarter 2026 Financial Results and Business Update Conference Call on August 12, 2026 Life Science Investing
Marvel Biosciences Reports Positive Preclinical Data Demonstrating MB-204 Reverses Behavioural and Cognitive Deficits in a Mouse Model of Fragile X Life Science Investing
